Fisiopatolojia di kankru di próstata ta mostra ma ten txeu tipu di prubléma.
Kanseru di próstata é un tumor malignu ki ta surji na sélulas di próstata, ki é un órgon pikinoti, ku fórma di nogósi, ki ta fika na baxu di bexiga na ómis.
Pur isu, el ta djuda-l kria sémen.
Ka sabedu pamodi ki ten kankru na próstata.
Kes-li ta inklui idadi, stória di família, rasa i alguns mutason jenétiku.
Kanseru di próstata é más kumun na ómis más grandi, ku maioria di kazus ki ta kontise na ómis ku más di 65 anu.
Tanbê, kes ómi ki ten família ki dja pasa pa mésmu tipu di duénsa, ten más xansi di panha kel tipu di duénsa li.
Duénsa di kánser di próstata é ka fásil di kontrola.
Kel-li pode kontise pamodi mutason na genes ki ta poi alguns párti di kel kriansa fika más txeu ô pamodi genes ki ta poi kel algen ta bira más bédju ka ta trabadja más.
Kes mudansa li pode poi sélulas ta kria sen faze nada i kel-la pode poi algen ten un tumor.
Sima tumor ta bira más grandi, el pode invadi tisidu i órgons pértu, sima bexiga, retal i nódulus linfátiku.
Na alguns kazu, sélulas di kankru pode kebra di tumor primáriu i spadja pa otus párti di korpu através di sangi ô sistema linfátiku, un prusésu konxedu pa metástasi.
Óras ki kankru spadja, é difísil kura-l.
Kanseru di próstata tanbê pode ser influensiadu pa fatoris hormonal, prinsipalmenti pa ormon andrójenu testosterona.
Testósterona pode poi sélulas di kankru di próstata ta kria.
Na kel studu li, nu odja ma kel tipu di kankru li é ka bon pa saúdi.
Konprende kes mekanismu basiku di duensa e crucial pa disenvolvimentu di tratamentus ifetivu i midjora rezultadus pa pasientis ku kankru di próstata.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Diskrison: médiku']
['Es site é sô pa studa i pa da informason.']
['Kes informason li ka debe uzadu pa faze diagnóstiku ô pa kura algun prubléma di saúdi.']
['Pur favor, toma nota ma redi neuronal ki ta jenera respóstas pa perguntas, é spesialmenti inakuradu óras ki ta papiadu di konteúdu numériku. Pur izénplu, nunbru di pesoas diagnostikadu ku un duénsa spesifiku.']
['Sénpri buska konsedju di bu médiku ó otu prestador di kuidadu di saúdi kualifikadu sobri un kondison médiku. Nunka ka bu nega konsedju di médiku profisional ô atrasa na buska-l pamodi algun kuza ki bu lé na es pájina. Si bu atxa ma bu pode ten un imerjénsia médiku, txoma 911 ô bai pa kuartu di imerjénsia más pértu imediatamenti.']
['Diskubri autor']
['Lei di Direitus Umanu Digital di 1998, 17 U.S.C. § 512 (o DMCA) ta dispunibiliza rikursus pa titular di direitus ki ta atxa ma material ki ta parsi na Internet ta viola ses direitus di akordu ku lei di direitus di autor di Stadus Unidus. ']
['Si bu kré, di bon fé, ki kualker kontiudu ô material disponibilizadu na nos site ô servisus ta viola bu direitus di autor, bo (ô bu ajenti) podi manda-nu un avizu ta pidi pa retiradu ô blokia es konteúdu ô material.']
['Nu ten ki manda un mensaji pa email (odja "Contact" pa kel email).']
['Es lei ta iziji ki bu notifikason di alegadu violason di copyright inklui kes siginti informason: (1) un deskripson di obra protejedu pa copyright ki e sujetu di alegadu violason; (2) un deskripson di kel konteúdu alegadu y informason sufisienti pa permiti-nu lokaliza kel konteúdu; (3) informason di kontatu pa bo, inkluindu bu enderesu, númeru di tilifon i enderesu di email; (4) un deklarason di bo ki ten un bon fé ma kel konteúdu di forma reklamadu ka e autorizadu pa donu di copyright, o pa se ajenti, o pa kualker lei; ']
['5. un deklarason di bu senhoriu, asinadu sob pena di perjúriu, ma informason na notifikason é izatu y ma bu ten autoridadi pa pratika kel direitu di autor ki foi violadu;']
['i (6) un asinatura fíziku ô iletróniku di kel algen ki é donu di direitus di autor ô di un algen ki sta autorizadu pa aji na se nómi.']
['Si bu ka da tudu informason, kel informason pode dimora txeu ténpu.']
['Kontaktu di Grupu']
['Pur favor, manda-nu email ku kalker pergunta/sugeston.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na kel ténpu']
['BioMedLib ta uza konputador automatizadu (algoritmus di aprendizagen di mákina) pa gera pares di pergunta y rasposta.']
['Nu ta kumesa ku 35 milhon di publikason biomédicu di PubMed/Medline. tanbê pájinas di internet di RefinedWeb.']
